Education
About Us
Working with TipRanks
Follow Us
Accelerate Diagnostics, Inc. (AXDXQ)
:AXDXQ
AXDXQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $2.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)3.77M
Market Cap
$156.30K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
Aug 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding25,210,392
10 Day Avg. Volume172,034
30 Day Avg. Volume3,767,453
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Accelerate Diagnostics News
PremiumCompany Announcements
Accelerate Diagnostics Files for Chapter 11 Bankruptcy
PremiumCompany Announcements
Accelerate Diagnostics CFO Resignation AnnouncedOwnership Overview
38.17%
Insiders
2.39%
Mutual Funds
12.07% Other Institutional Investors
47.37% Public Companies and
Individual Investors
AXDXQ FAQ
What was Accelerate Diagnostics, Inc.’s price range in the past 12 months?
Accelerate Diagnostics, Inc. lowest stock price was <$0.01 and its highest was $2.09 in the past 12 months.
What is Accelerate Diagnostics, Inc.’s market cap?
Accelerate Diagnostics, Inc.’s market cap is $156.30K.
When is Accelerate Diagnostics, Inc.’s upcoming earnings report date?
Accelerate Diagnostics, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 32 days.
How were Accelerate Diagnostics, Inc.’s earnings last quarter?
Currently, no data Available
Is Accelerate Diagnostics, Inc. overvalued?
According to Wall Street analysts Accelerate Diagnostics, Inc.’s price is currently Overvalued.
Does Accelerate Diagnostics, Inc. pay dividends?
Accelerate Diagnostics, Inc. does not currently pay dividends.
What is Accelerate Diagnostics, Inc.’s EPS estimate?
Accelerate Diagnostics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Accelerate Diagnostics, Inc. have?
Accelerate Diagnostics, Inc. has 25,210,392 shares outstanding.
What happened to Accelerate Diagnostics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Accelerate Diagnostics, Inc.?
Currently, no hedge funds are holding shares in AXDXQ
Company Description
Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Technical Analysis
American Shared Hospital Services
―
Palatin Technologies
―
ImmunoPrecise Antibodies
―
Nephros
―
Vivos Therapeutics
―